Lia,

I hate to sound like Itell but that is "interesting".Their product is sounding more shakey by the moment.The original article stated that Biocon's version of the pill didn't work out as planned either.

Thanks yet again.

"Other companies are also working to commercialize oral insulin. Denmark’s Novo Nordisk announced earlier this year that their oral insulin completed the very earliest stage of clinical testing. Biocon, out of India, conducted a Phase 3 trial of its insulin pill in India, but the drug did not meet expectations.In a recent conversation, Dr. Ehud Arbit, Director of Research and Development at Oramed, said it was likely that Oramed would be marketed in the U.S. before Biocon because the unsatisfactory results of Biocon’s phase 3 trial will slow its progress with the pill."